Home
About
Team
Portfolio
News
FAQ
Contact

News

BioAdvance Commits $4M to 14 Life Sciences Companies

Aug 14, 2017

BioAdvance Commits $4M to 14 Life Sciences Companies

Comments are closed.

Current News

HueDx Transforms Point-of-Care Diagnostics with AI-Powered Smartphone Solutions
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
Wellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

© 2013-2024 BioAdvance. All rights reserved.